Medikra Inc.

F-1/A amended

Medikra Inc. is conducting an initial public offering (IPO) of 4,545,455 ordinary shares at an expected price range of $5 to $6 per share. The offering includes a 15% over-allotment option and a warrant for underwriters to purchase 5% of shares. The company aims to list on Nasdaq, with the offering conditioned on approval. The filing reflects adjustments from the previous F-1, including a revised exchange target (Nasdaq vs. NYSE American), increased share count, and updated underwriting terms.

F-1 filed

Medikra Inc. is conducting an initial public offering (IPO) of 3,636,364 ordinary shares, with an expected price range of $5 to $6 per share. The company, a Cayman Islands holding company, operates through its Malaysian subsidiaries and plans to list on the NYSE American. The offering includes underwriting discounts of 7% per share, a warrant for underwriters to purchase 7% of shares, and a 15% over-allotment option. The filing confirms the company's status as an emerging growth company and foreign private issuer, with risks including exchange rate fluctuations and reliance on subsidiaries.

DRS/A amended

Medikra Inc. is conducting an initial public offering (IPO) of its ordinary shares, with an expected price range of $[●] to $[●] per share. The offering is being underwritten by Brookline Capital Markets, a division of Arcadia Securities, LLC. The company plans to list its shares on the NYSE American and has reserved the symbol MDKR. The IPO includes a 15% over-allotment option and a warrant for underwriters. Medikra is an emerging growth company and a foreign private issuer, subject to reduced reporting requirements. The offering is on a firm commitment basis, with proceeds intended for general corporate purposes.

DRS filed

Medikra Inc., a Cayman Islands exempted company, is conducting an initial public offering (IPO) of its ordinary shares, with an expected price range of $[*] to $[*] per share. The offering is structured on a firm commitment basis, with Brookline Capital Markets as the underwriter. The company plans to list its shares on the NYSE American, contingent on regulatory approval. Medikra operates through subsidiaries in Malaysia, conducting business in MYR while financial statements are presented in USD. The filing highlights risks including high volatility, exchange rate fluctuations, and lack of prior public market liquidity.